Kim Hee Joo, Werth Victoria P
Department of Dermatology, Gachon Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.
Ann Dermatol. 2024 Oct;36(5):257-265. doi: 10.5021/ad.24.022.
Dermatomyositis (DM) is a rare autoimmune connective tissue disease with characteristic skin manifestations and possible muscle involvement. Recent advances in classification system to include skin-predominant subtypes, understanding underlying pathogenic mechanisms and the relationship between clinical phenotypes and myositis-specific autoantibodies have led to development of novel therapeutic options. This corresponds with efforts to develop better outcome measures to accurately catch the patients' current disease status and treatment-induced improvements. This report will review the updates in newer treatments and outcome measures of DM, specifically from a dermatologic point of view.
皮肌炎（DM）是一种罕见的自身免疫性结缔组织病，具有特征性的皮肤表现，可能累及肌肉。分类系统的最新进展，包括以皮肤为主的亚型、对潜在致病机制的理解以及临床表型与肌炎特异性自身抗体之间的关系，已促成了新治疗方案的开发。这与开发更好的疗效评估指标以准确掌握患者当前疾病状态和治疗引起的改善情况的努力相一致。本报告将从皮肤病学角度回顾皮肌炎新治疗方法和疗效评估指标的最新进展。
